Thyroid Cancers

Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer

September 19, 2020

Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers

September 05, 2020

The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.

Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness Month

September 02, 2020

In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the evolution she has observed in thyroid cancer in terms of the use of targeted therapies and other important milestones for this patient population.